PRNewsWire
01 Sept 2026, 10:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Medtronic raised its fiscal 2027 organic revenue growth guidance to 7.25%–7.75% and increased its non-GAAP EPS guidance to $5.94–$6.00. — Upward revisions to full-year top and bottom-line guidance are strong bullish signals for stock price appreciation.
+0.60Q1 worldwide revenue grew 13.7% to $9.756 billion, with non-GAAP diluted EPS increasing 15.1% to $1.45. — Strong double-digit growth in both revenue and earnings demonstrates operational momentum and portfolio strength.
+0.40An extra fiscal week in Q1 FY27 contributed approximately $570 million to the organic growth figures. — This provides a necessary correction to the growth figures, showing that a portion of the beat was due to calendar effects rather than purely organic demand.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company reported strong Q1 revenue and profit growth and raised its full-year organic revenue and EPS guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
WSJ
25m ago
